Journavx to Treat Pain After Thumb Basal Joint Arthroplasty | NCT07723352

NCT07723352

Overview

NCT ID: NCT07723352
Lead Sponsor: Rothman Institute OrthopaedicsOTHER
Official Title: A Single-Arm Open-Label Trial Evaluating the Efficacy of Suzetrigine (Journavx) in Multimodal Postoperative Pain Management Following Thumb Basal Joint Arthroplasty
Brief Summary: The purpose of this study is to find out how well suzetrigine, a newly FDA-approved non-opioid pain medication, works to relieve pain after thumb basal joint replacement surgery. The researchers believe that suzetrigine may provide effective pain relief during recovery without the use of opioid medications.
Conditions: Thumb Basal Joint Osteoarthritis
Postoperative Pain
Joint Replacement Surgery
Joint Replacement

Ages Eligible for Study: Adult (18-64)Older Adult (65+)
Sexes Eligible for Study: All
Accepts Healthy Volunteers?: Yes
Eligibility Criteria: Inclusion Criteria:

Aged 40-80 years.

Undergoing thumb basal joint arthroplasty (BJA)

Able to provide informed consent.

Willing to comply with the study procedures.

Exclusion Criteria:

History of substance abuse or chronic opioid use.

Known allergies to acetaminophen, oxycodone, or suzetrigine.

Severe renal or hepatic dysfunction

Estimated glomerular filtration rate less than 15 ml/min/1.73m^2

History of kidney transplant

Child-Pugh Class C

History of liver failure

Active hepatitis that can adversely influence hepatic function

Has had prior surgery on the study hand within the last 6 months

Is currently pregnant, planning to be pregnant, or breastfeeding

Use of strong or moderate CYP3A inhibitors or inducers, or medications known to interact with suzetrigine

Currently using a prescription pain medication other study medications